The progress made by antibiotic start-up Spero Therapeutics LLC offers a clear example of how the Generating Antibiotic Incentives Now provisions have helped reinvigorate research in the infectious disease space. In an interview with the Pink Sheet, Spero CEO Ankit Mahadevia noted that the GAIN incentives enabled his firm not only to raise about $65m across Series A and B financings, but also will open up an accelerated approval pathway for the firm's novel drugs.
Approved in 2012 as part of the last Prescription Drug User Fee Act reauthorization, the GAIN provisions added regulatory clarity,...